Results 51 to 60 of about 19,019 (189)

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

Retrovirology, 2017
Background HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration.
Céline Amadori, Yme Ubeles van der Velden, Damien Bonnard, Igor Orlov, Nikki van Bel, Erwann Le Rouzic, Laia Miralles, Julie Brias, Francis Chevreuil, Daniele Spehner, Sophie Chasset, Benoit Ledoussal, Luzia Mayr, François Moreau, Felipe García, José Gatell, Alessia Zamborlini, Stéphane Emiliani, Marc Ruff, Bruno P. Klaholz, Christiane Moog, Ben Berkhout, Montserrat Plana, Richard Benarous   +23 more
doaj   +1 more source

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

Viruses, 2014
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

The use of integrase inhibitors in treatment-experienced patients [PDF]

European Journal of Medical Research, 2009
Raltegravir, the first approved HIV-1 integrase inhibitor, is able to block the strand transfer step of the HIV proviral DNA integration process into the cellular host DNA. The selected dosage for the pivotal phase III studies (subsequently approved by the regulatory agencies) was 400mg bid by oral route with or without food.
openaire   +4 more sources

Intrapatient Development of Multi-Class Drug Resistance in an Individual Infected with HIV-1 CRF01_AE

Infection and Drug Resistance, 2021
Xiaorong Peng,* Yufan Xu,* Ying Huang, Biao Zhu State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China*These ...
Peng X, Xu Y, Huang Y, Zhu B
doaj  

CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects

Journal of Translational Medicine, 2004
Background CD8+ T cell responses are known to be important to the control of HIV-1 infection. While responses to reverse transcriptase and most structural and accessory proteins have been extensively studied, CD8 T cell responses specifically directed to
Yu Xu G, Fitzpatrick Cecily A, Rathod Almas, Addo Marylyn M, Rodriguez William R, Perkins Beth, Rosenberg Eric S, Altfeld Marcus, Walker Bruce D   +8 more
doaj   +1 more source

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj  

Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry Reports
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking
Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi   +4 more
doaj  

2-Mercaptobenzenesulphonamides as Novel Inhibitors of Human Immunodeficiency virus Type 1 Integrase and Replication [PDF]

, 1997
Nouri Neamati, Abhijit Mazumder, Sanjay Sunder, J. M. Owen, R.J. Schultz, Yves Pommier   +5 more
openalex   +1 more source

Integrase inhibitor‐based treatment in clinical practice

Journal of the International AIDS Society, 2010
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
M Feasi, N Bobbio, R Piscopo, Giovanni Cassola, Giovanni Cenderello, Giovanni Penco   +5 more
openaire   +2 more sources

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj